PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
Petrylak, Daniel P., Vogelzang, Nicholas J., Chatta, Kamal, Fleming, Mark T., Smith, David C., Appleman, Leonard J., Hussain, Arif, Modiano, Manuel, Singh, Parminder, Tagawa, Scott T., Gore, Ira, McClLanguage:
english
Journal:
The Prostate
DOI:
10.1002/pros.23922
Date:
November, 2019
File:
PDF, 941 KB
english, 2019